3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Leukemia, Myeloid, Acute
17
Leukemia, Promyelocytic, Acute
10
Leukemia
9
Myelodysplastic Syndromes
8
Melanoma
5
Congenital Abnormalities
4
Myeloproliferative Disorders
3
Myelodysplastic-Myeloproliferative Diseases
3
Multiple Myeloma
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Erythroblastic, Acute
3
Uterine Cervical Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neuroblastoma
2
Lymphoma, T-Cell, Cutaneous
2
Leukemia, Myelomonocytic, Chronic
2
Anemia, Refractory, with Excess of Blasts
2
Wilms Tumor
1
Uterine Cervical Dysplasia
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Neoplasm Metastasis
1
Lymphoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Interventions
pembrolizumab
125
Cisplatin
28
Carboplatin
25
lenvatinib
24
Paclitaxel
20
Docetaxel
16
Fluorouracil
13
Pemetrexed
11
Capecitabine
11
Gemcitabine
10
Saline Solution
8
Oxaliplatin
8
epacadostat
6
Leucovorin
5
Irinotecan
5
Cetuximab
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
olaparib
4
Bevacizumab
4
trifluridine tipiracil drug combination
3
regorafenib
3
enzalutamide
3
durvalumab
3
Nivolumab
3
Etoposide
3
trametinib
2
etoposide phosphate
2
dabrafenib
2
Tretinoin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Tretinoin
×
Clear all
NCT04303169
2025-10-27
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
146 enrolled
NCT04305041
2025-08-29
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
100 enrolled